Stay updated with breaking news from Current Prescribing. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic profile based on the relevant PK modeling data Additional...
PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable formulation of risperidone microspheres Additional UZEDY...
RISE data show UZEDY to be an effective long-acting injectable antipsychotic treatment option for adults with schizophrenia, with a known safety profile consistent with other formulations of...
02.11.2023 - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy and safety findings from the phase 3 Risperidone Subcutaneous Extended-Release (RISE) study in The ...
RISE data show UZEDY to be an effective long-acting injectable (LAI) antipsychotic treatment option for adults with schizophrenia, with a known safety profile consistent with other formulations of risperidone1In the RISE study, UZEDY significantly prolonged time to impending relapse by up to 5.0 times (once-monthly...